Research
Hormonal
SGLT2 inhibitors protect kidney function by restoring tubuloglomerular feedback, which reduces glomerular hyperfiltration and intraglomerular pressure, thereby indirectly reducing cardiovascular disease risk.
SGLT2 inhibitors protect your kidneys by reducing pressure inside the kidney filters, which also helps protect your heart, as kidney health is closely linked to heart health.
GoodSupportsHIGH confidence
Restored tubuloglomerular feedback by SGLT2 inhibitors might play a role in renoprotection, which in turn, leads to fewer CVDs.
Why this rating
Supported by large clinical trials showing renal benefits.
Source
The Potential Cardioprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors
Jae‐Han Jeon · Journal of Korean Diabetes · 2019
DOI 10.4093/jkd.2019.20.2.81
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT2 inhibitors provide cardioprotection through hemodynamic improvements, specifically by reducing preload and afterload via osmotic diuresis and natriuresis, which decreases ventricular wall tension and myocardial oxygen consumption.Good
- SGLT2 inhibitors improve cardiac energy efficiency in failing diabetic hearts by shifting fuel utilization from fatty acids to ketone bodies, which act as a 'super-fuel' that generates ATP more efficiently.Good
- SGLT2 inhibitors reduce systemic inflammation and oxidative stress by decreasing body fat mass and improving insulin resistance, which lowers inflammatory markers like IL-6 and TNF-alpha.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →